Inhaled corticosteroid dose-response on blood eosinophils in asthma

Lipworth, Brian J.; Jabbal, Sunny; Manoharan, Arvind; Anderson, William J.; Short, Philip

doi:10.1016/s2213-2600(15)00504-4

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 Dose-response relationships between prescribed ICS and elevated blood eosinophil counts in patients with severe asthma should therefore be assessed in future studies. 30 One third of our study population prescribed medication within GINA steps 3 and 4 were current smokers, with more than 10% former smokers. Previous studies have reported that smoking hinders response to ICS treatment 31,32 , and smoking status is therefore likely to confound the relationship between adherence to ICS treatment and symptom outcomes.…”

Section: Discussionmentioning

confidence: 99%

Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma

Papi

Ryan

Soriano

et al. 2018

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma

Papi

Ryan

Soriano

et al. 2018

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

show abstract

Diagnosing Asthma with and without Aerosol-Generating Procedures

Drake

Wang

Healy

et al. 2021

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial

et al. 2018

View full text Add to dashboard Cite

BackgroundFluticasone furoate/Vilanterol trifenatate (FF/VI) is an inhaled corticosteroid/long-acting beta-agonist combination with a prolonged bronchodilator duration of action. We characterised the time-course of onset and offset of airway anti-inflammatory action of FF/VI, as assessed by fraction of exhaled nitric oxide (FeNO), and compared this to the bronchodilator duration of action.MethodsA single-centre, randomised, double-blind, placebo-controlled, two-period, crossover study was undertaken in 28 steroid-naïve adults with asthma. Participants with an FEV1 ≥ 60% predicted, reversible airway disease, and FeNO > 40 ppb received FF/VI 100/25 mcg or placebo once daily for 14 days. FeNO and peak expiratory flow were measured twice-daily during treatment and during a 21-day washout period. FEV1 was measured for five days from treatment cessation. The primary outcome measure was FeNO change from baseline ratio for 21 days following treatment cessation.ResultsIn the 27 subjects who completed the study, median (range) baseline FeNO was 87 ppb (42–212). FF/VI 100/25 mcg reduced FeNO by day 3, ratio FF/VI versus placebo 0.72 (95% confidence interval 0.61–0.86) with the maximum reduction occurring at day 14, 0.32 (0.27–0.37). Following cessation of treatment FeNO remained suppressed for 18 days, ratio on day 18 0.77 (0.59–1.00), whereas improvements in FEV1 and peak flow were maintained for 3 to 4 days post-treatment.ConclusionsThe anti-inflammatory duration of action of FF/VI is consistent with the high glucocorticoid receptor affinity and long lung retention of fluticasone furoate. The anti-inflammatory effect of FF/VI was of greater duration than its bronchodilator effect in adults with mild asthma.Funding GlaxoSmithKline (201499).Trial registrationProspectively registered on ClinicalTrials.gov registry number NCT02712047.Electronic supplementary materialThe online version of this article (10.1186/s12931-018-0836-6) contains supplementary material, which is available to authorized users.

show abstract

Inhaled corticosteroid dose-response on blood eosinophils in asthma

Cited by 3 publications

References 8 publications

Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma

Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma

Diagnosing Asthma with and without Aerosol-Generating Procedures

Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial

Contact Info

Product

Resources

About